Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Eight new medicines recommended for approval

The Committee for Medicinal Products for Human Use has recommended the approval of Giotrif for the treatment of lung cancer.

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Giotrif for the treatment of lung cancer. The CHMP also recommended that Incresync, Vipdomet and Vipidia should be granted marketing authorisations for the treatment of type 2 diabetes. UltibroBreezhaler and XoternaBreezhaler received positive opinions from the Committee for the treatment of chronic obstructive pulmonary disease (COPD).  The Committee recommended that Tybost should be granted a marketing authorisation for the treatment of human immunodeficiency virus-1 (HIV-1) infection in combination with protease inhibitors atazanavir and darunavir. The Committee also gave a positive recommendation for the approval of Grastofil, a biosimilar medicine for

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy